Phaco benefits on IOP even better

Article

Instead of combined surgery, cataract extraction alone by phacoemulsification through a clear corneal incision with posterior chamber IOL implantation may be the most appropriate procedure for patients with controlled or modestly uncontrolled glaucoma as well as for patients with ocular hypertension or glaucoma suspects.

Instead of combined surgery, cataract extraction alone by phacoemulsification through a clear corneal incision with posterior chamber IOL implantation may be the most appropriate procedure for patients with controlled or modestly uncontrolled glaucoma as well as for patients with ocular hypertension or glaucoma suspects.

"It may be that a lot of adult glaucoma is 'phacomorphic', and perhaps the best therapy is to remove the crystalline lens," said Richard L. Lindstrom, MD, founder and attending surgeon, Minnesota Eye Consultants, Minneapolis, US.

Dr Lindstrom presented evidence that the lowering achieved in eyes presenting with higher levels of IOP is much greater than realized.

To investigate the effect of cataract surgery on IOP, he undertook retrospective analyses. Dr Lindstrom found that the amount of IOP reduction after cataract surgery was proportional to the presurgical IOP and quite significant in those at the higher end of the spectrum. He then conducted a literature review, in which eyes from previously reported papers were stratified based on their presurgical IOP. Consistent with his own retrospective analyses, the results showed that in eyes with higher IOP, average decreases of at least 8–10 mmHg were achieved.

Additional evidence of the benefit of phacoemulsification on elevated IOP derives from an analysis of conversion rates of ocular hypertension to glaucoma after cataract surgery. Dr Lindstrom reported that the outcomes of his patient series compared very favourably with data reported in the Ocular Hypertension Treatment Study.

"Perhaps as patients develop elevated IOP and we are getting ready to treat that finding, we should consider if they might have an indication for lens removal, including early cataract, significant refractive error, or dissatisfaction because of presbyopia, and offer these patients the option of our fantastic operation of phacoemulsification with a posterior chamber IOL," Dr Lindstrom concluded.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.